Free tool
FAERS Monitor: Opipza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216655 or its brand name (Opipza, Aripiprazole). Reports on generic versions are filed under their own applications.
Reports
42,264
Serious
35,961
85% of reports
Hospitalization
16,723
Death reported
3,404
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,421
- off label use2,952
- drug interaction2,286
- product use in unapproved indication2,270
- weight increased2,162
- anxiety1,796
- condition aggravated1,712
- suicide attempt1,582
- fatigue1,545
- suicidal ideation1,449
- toxicity to various agents1,429
- nausea1,385
- somnolence1,363
- sedation1,318
- schizophrenia1,305
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 68 |
| 2005 | 111 |
| 2006 | 161 |
| 2007 | 217 |
| 2008 | 192 |
| 2009 | 256 |
| 2010 | 342 |
| 2011 | 354 |
| 2012 | 534 |
| 2013 | 428 |
| 2014 | 584 |
| 2015 | 1,211 |
| 2016 | 1,456 |
| 2017 | 2,955 |
| 2018 | 3,363 |
| 2019 | 3,484 |
| 2020 | 3,049 |
| 2021 | 3,704 |
| 2022 | 3,702 |
| 2023 | 4,151 |
| 2024 | 4,228 |
| 2025 | 4,180 |
| 2026 | 3,534 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,011,895 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| schizophreniaSignal | 1,305 | 59.8 | 56.5 | 67,286 |
| sedationSignal | 1,318 | 26.3 | 24.9 | 30,501 |
| suicide attemptSignal | 1,582 | 13.3 | 12.7 | 17,573 |
| suicidal ideationSignal | 1,449 | 8.0 | 7.6 | 8,749 |
| drug interactionSignal | 2,286 | 7.3 | 7.0 | 12,250 |
| weight increasedSignal | 2,162 | 4.8 | 4.6 | 6,593 |
| product use in unapproved indicationSignal | 2,270 | 4.6 | 4.4 | 6,389 |
| toxicity to various agentsSignal | 1,429 | 4.2 | 4.0 | 3,539 |
| somnolenceSignal | 1,363 | 3.4 | 3.2 | 2,294 |
| anxietySignal | 1,796 | 3.2 | 3.0 | 2,659 |
| condition aggravatedSignal | 1,712 | 2.8 | 2.7 | 2,016 |
| off label use | 2,952 | 1.7 | 1.6 | 844 |
| drug ineffective | 4,421 | 1.7 | 1.6 | 1,268 |
| fatigue | 1,545 | 1.0 | 0.9 | 0 |
| nausea | 1,385 | 0.9 | 0.8 | 27 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.